Renaissance Technologies’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-40,850
| Closed | -$1.14M | – | 3925 |
|
|
2023
Q4 | $1.14M | Buy |
+40,850
| New | +$1.07M | ﹤0.01% | 2318 |
|
|
2023
Q2 | – | Sell |
-19,910
| Closed | -$2.26M | – | 4127 |
|
|
2023
Q1 | $2.26M | Sell |
19,910
-7,665
| -28% | -$829K | ﹤0.01% | 1954 |
|
|
2022
Q4 | $3.09M | Buy |
27,575
+630
| +2% | +$84.5K | ﹤0.01% | 1802 |
|
|
2022
Q3 | $3.46M | Sell |
26,945
-16,875
| -39% | -$1.73M | ﹤0.01% | 1667 |
|
|
2022
Q2 | $3.01M | Buy |
43,820
+19,850
| +83% | +$1.71M | ﹤0.01% | 1907 |
|
|
2022
Q1 | $3.41M | Sell |
23,970
-13,355
| -36% | -$2.05M | ﹤0.01% | 1840 |
|
|
2021
Q4 | $6.22M | Buy |
+37,325
| New | +$5.93M | 0.01% | 1381 |
|
|
2021
Q2 | – | Sell |
-6,460
| Closed | -$2.66M | – | 3660 |
|
|
2021
Q1 | $2.66M | Buy |
6,460
+1,410
| +28% | +$649K | ﹤0.01% | 2033 |
|
|
2020
Q4 | $2.48M | Sell |
5,050
-13,790
| -73% | -$8.08M | ﹤0.01% | 1989 |
|
|
2020
Q3 | $10.7M | Sell |
18,840
-50,825
| -73% | -$16.9M | 0.01% | 1082 |
|
|
2020
Q2 | $6.63M | Buy |
69,665
+15,825
| +29% | +$1.39M | 0.01% | 1467 |
|
|
2020
Q1 | $3.84M | Sell |
53,840
-1,930
| -3% | -$129K | ﹤0.01% | 1712 |
|
|
2019
Q4 | $3.85M | Buy |
55,770
+1,810
| +3% | +$134K | ﹤0.01% | 2009 |
|
|
2019
Q3 | $4.33M | Buy |
53,960
+1,790
| +3% | +$118K | ﹤0.01% | 1875 |
|
|
2019
Q2 | $3.36M | Buy |
52,170
+7,060
| +16% | +$670K | ﹤0.01% | 2054 |
|
|
2019
Q1 | $6.2M | Buy |
45,110
+4,865
| +12% | +$593K | 0.01% | 1672 |
|
|
2018
Q4 | $3.64M | Buy |
40,245
+2,415
| +6% | +$338K | ﹤0.01% | 1923 |
|
|
2018
Q3 | $5.74M | Buy |
37,830
+1,235
| +3% | +$200K | 0.01% | 1710 |
|
|
2018
Q2 | $6.29M | Sell |
36,595
-7,295
| -17% | -$1.19M | 0.01% | 1629 |
|
|
2018
Q1 | $6.44M | Sell |
43,890
-1,670
| -4% | -$320K | 0.01% | 1655 |
|
|
2017
Q4 | $9.24M | Buy |
45,560
+14,915
| +49% | +$3.06M | 0.01% | 1438 |
|
|
2017
Q3 | $9.83M | Buy |
30,645
+7,630
| +33% | +$2.09M | 0.01% | 1337 |
|
|
2017
Q2 | $5.2M | Buy |
23,015
+5,475
| +31% | +$1.12M | 0.01% | 1686 |
|
|
2017
Q1 | $3.95M | Sell |
17,540
-2,475
| -12% | -$502K | 0.01% | 1832 |
|
|
2016
Q4 | $3.96M | Buy |
20,015
+5,190
| +35% | +$1.13M | 0.01% | 1821 |
|
|
2016
Q3 | $3.64M | Buy |
+14,825
| New | +$5.2M | 0.01% | 1810 |
|
|
2015
Q4 | – | Sell |
-545
| Closed | -$323K | – | 3364 |
|
|
2015
Q3 | $323K | Buy |
+545
| New | +$445K | ﹤0.01% | 2745 |
|
Other funds holding MCRB
FP
WP
EP
Renaissance Technologies's MCRB Position: Q1 2024 in Review
Renaissance Technologies sold out of Seres Therapeutics (MCRB) in Q1 2024, closing a stake of 40,850 shares — an estimated $1.14M sold.
Renaissance Technologies first reported a position in MCRB in Q3 2015 and held it in 27 quarters. The position peaked at $10.7M in Q3 2020. 99 funds tracked by Wall St. Rank hold MCRB as of Q1 2024.
- Renaissance Technologies reported no remaining Seres Therapeutics position as of Q1 2024 after selling out during the quarter.
- Renaissance Technologies sold 40,850 Seres Therapeutics shares in Q1 2024, an estimated $1.14M.
- Renaissance Technologies first reported a position in Seres Therapeutics in Q3 2015 and held it in 27 quarters.
- Renaissance Technologies's Seres Therapeutics position peaked at $10.7M in Q3 2020.
- 99 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2024.
Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.